From Genetic Discoveries to New Therapies

Creating small molecule therapies to treat disease

About Tollbridge Therapeutics

About Tollbridge Therapeutics

 Tollbridge Therapeutics is developing innovative therapies that harness the immune system to fight cancer and other diseases. Founded by two leading scientists, including a 2011 Nobel Laureate for Physiology or Medicine, Tollbridge Therapeutics has started pre clinical trials on our lead compound, Diprovocim

Diprovocim

Our lead compound, Diprovocim, is a powerful adjuvant  that triggers the body's immune system to fight diseases such as cancer.  Currently in preclinical studies, see the recent paper in PNAS about its effectiveness in treating melanoma in mice

Our Pipeline

Through our partnerships with The Scripps Research Institute and University of Texas - Southwestern, Tollbridege is building a portfolio of promising targets and creating innovative therapies

Management Team

Earl B. Beutler, CEO

 Earl Beutler is an experienced executive who has founded and managed multiple successful companies in the scientific and academic communities including Research Information Systems, RefWorks, and LabArchives 

Bryan Hong Woo Kim, CSO

   Dr. Bryan (Hong Woo) Kim, a serial entrepreneur, medicinal chemist, joins Tollbridge Therapeutics as CSO with 21 years of various therapeutic discovery and development experience along with senior leadership at biotech companies in US as well as in Korea.  


  

Dr. Kim received his PhD in organic chemistry from University of Nebraska, Lincoln, and B.Sc. and M. Sc. from Korea University, Korea. He has authored multiple peer-reviewed publications as well as patents. Dr. Kim is also a member of the American Chemical Society.

Todd Jones, Science Director

  Todd Jones, Ph.D., has over twenty years of experience in drug discovery and development in both pharmaceutical and biotechnology companies. He is a co-founder of Abide Therapeutics. 

  Todd served as Vice President of Chemistry & Enabling Technologies at Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) where he had responsibility for establishing, building and guiding Medicinal Chemistry, Biology Enabling Research Technologies (Compound Logistics, Developability, Drug Metabolism & Pharmacokinetics, Genomics and High Throughput Screening), Scale-up Chemistry, Analytical Chemistry, and Computational Chemistry. During Todd’s leadership tenure, the J&JPRD La Jolla site generated over thirty new molecular entities that were accepted into development with more than fifteen advancing into human clinical trials. 

Scientific Advisors

Bruce Alan Beutler, M.D.

 Bruce Alan Beutler is an American immunologist and geneticist. Together with Jules A. Hoffmann, he received one-half of the 2011 Nobel Prize in Physiology or Medicine, for "their discoveries concerning the activation of innate immunity." 

Dale Boger, Ph.D.

 Dale Lester Boger is an American medicinal and organic chemist and chair of the Department of Chemistry at The Scripps Research Institute in La Jolla, CA 

Subscribe

Investors and Partners

Interested in partnering with Tollbridge?

Please complete our Contact Form for more information

 

Contact Us

Send Message

Please send us a message or call us for an appointment. 

 

Feel free to fax any documents to (509) 352-9699

Tollbridge Therapeutics

1915 Aston Ave, Carlsbad, CA 92008, us

(858) 877-3275

Hours

Monday - Friday: 8:00am - 5:00pm

Saturday - Sunday: Closed